These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26072332)

  • 21. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
    Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
    Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
    Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM
    Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
    Lee CR; Kang JA; Kim HE; Choi Y; Yang T; Park SG
    FEBS Lett; 2016 Feb; 590(3):358-68. PubMed ID: 26831735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
    Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
    BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
    Vatanmakanian M; Tavallaie M; Ghadami S
    Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia.
    Su R; Wen Z; Zhan X; Long Y; Wang X; Li C; Su Y; Fei J
    Cell Death Dis; 2024 Aug; 15(8):615. PubMed ID: 39179585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
    Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
    Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
    Shih LY; Kuo MC; Kuo CY; Lin TH; Bai LY; Chen TY; Wang MC; Lin TL; Lan YJ; Chen CC; Yang Y; Hsiao PC; Lai CL; Chang CH; Lin TH
    Leuk Res; 2013 Jan; 37(1):43-9. PubMed ID: 23062378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
    Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y
    Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
    McCarron SL; O'Connor LM; Langabeer SE; Conneally E
    Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p19
    Kuang Y; Han X; Cao P; Xiong D; Peng Y; Liu Z; Xu Z; Liang L; Roy M; Liu J; Nie L; Zhang J
    Blood Cells Mol Dis; 2020 Nov; 85():102477. PubMed ID: 32711219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.
    Salas A; Ponnusamy S; Senkal CE; Meyers-Needham M; Selvam SP; Saddoughi SA; Apohan E; Sentelle RD; Smith C; Gault CR; Obeid LM; El-Shewy HM; Oaks J; Santhanam R; Marcucci G; Baran Y; Mahajan S; Fernandes D; Stuart R; Perrotti D; Ogretmen B
    Blood; 2011 Jun; 117(22):5941-52. PubMed ID: 21527515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
    Quintás-Cardama A; Cortes J
    Blood; 2009 Feb; 113(8):1619-30. PubMed ID: 18827185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
    Feng H; Fu Y; Cui Z; Zhou M; Zhang L; Gao Z; Ma S; Chen C
    Br J Haematol; 2023 Sep; 202(6):1178-1191. PubMed ID: 37469124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
    Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
    BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
    Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
    Prado-Carrillo O; Arenas-Ramírez A; Llaguno-Munive M; Jurado R; Pérez-Rojas J; Cervera-Ceballos E; Garcia-Lopez P
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML).
    Marcé S; Cortés M; Zamora L; Cabezón M; Grau J; Millá F; Feliu E
    Exp Mol Pathol; 2015 Aug; 99(1):16-8. PubMed ID: 25913326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.